Luca Issi Analyst Performance

Senior Biotechnology Analyst at Royal Bank Of Canada

Luca Issi is a stock analyst at Royal Bank Of Canada focused in the medical sector, covering 26 publicly traded companies. Over the past year, Luca Issi has issued 38 stock ratings, including buy and hold recommendations. While full access to Luca Issi's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Luca Issi's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rating: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 39 Last 3 Years
Buy Recommendations: 69.23% 27 Buy Ratings
Companies Covered: 26 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	69.2%	27 ratings
Hold	30.8%	12 ratings
Sell	0.0%	0 ratings

Out of 39 total stock ratings issued by Luca Issi at Royal Bank Of Canada, the majority (69.2%) have been Buy recommendations, followed by 30.8% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	96.2% of companies on NASDAQ	25 companies
NYSE	3.8% of companies on NYSE	1 company

Luca Issi, an analyst at Royal Bank Of Canada, currently covers 26 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 25 companies	96.2%
	Energy 1 company	3.8%

Luca Issi of Royal Bank Of Canada specializes in stock coverage within the Medical sector, with additional focus on Energy companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 17 companies	65.4%
MED - DRUGS 7 companies	26.9%
OIL - FIELD SVCS 1 company	3.8%
PHARMACEUTICAL PREPARATIONS 1 company	3.8%

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
IONS Ionis Pharmaceuticals	9/4/2025	Boost Price Target	$60.56	$80.00	Outperform
ARGX argenex	8/25/2025	Initiated Coverage	$660.00	$850.00	Outperform
NTLA Intellia Therapeutics	8/8/2025	Lower Price Target	$10.72	$21.00	Outperform
ASND Ascendis Pharma A/S	8/8/2025	Boost Price Target	$190.21	$230.00	Outperform
ARWR Arrowhead Pharmaceuticals	8/8/2025	Lower Price Target	$16.10	$38.00	Outperform
RGNX REGENXBIO	8/8/2025	Lower Price Target	$7.82	$17.00	Outperform
CRSP CRISPR Therapeutics	8/5/2025	Boost Price Target	$53.14	$42.00	Sector Perform
FULC Fulcrum Therapeutics	7/30/2025	Boost Price Target	$6.96	$5.00	Sector Perform
DYN Dyne Therapeutics	7/29/2025	Lower Price Target	$8.94	$23.00	Outperform
ADVM Adverum Biotechnologies	5/15/2025	Lower Price Target	$1.91	$4.00	Sector Perform
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
ALLO Allogene Therapeutics	5/14/2025	Reiterated Rating	$0.90	$10.00	Outperform
APLS Apellis Pharmaceuticals	5/8/2025	Lower Price Target	$18.14	$18.00	Sector Perform
MRNA Moderna	5/2/2025	Lower Price Target	$27.54	$28.00	Sector Perform
ASND Ascendis Pharma A/S	4/16/2025	Initiated Coverage	$153.92	$205.00	Outperform
ADVM Adverum Biotechnologies	4/16/2025	Lower Price Target	$3.20	$5.00	Sector Perform
LXEO Lexeo Therapeutics	3/25/2025	Lower Price Target	$3.88	$20.00	Outperform
ALNY Alnylam Pharmaceuticals	3/21/2025	Boost Price Target	$281.35	$330.00	Outperform
KRRO Korro Bio	3/19/2025	Lower Price Target	$24.13	$95.00	Outperform
OCUL Ocular Therapeutix	3/18/2025	Initiated Coverage	$7.94	$17.00	Outperform
SGMO Sangamo Therapeutics	3/18/2025	Reiterated Rating	$0.86	$2.00	Sector Perform
MGTX MeiraGTx	3/17/2025	Boost Price Target	$7.77	$13.00	Outperform
ALLO Allogene Therapeutics	3/14/2025	Reiterated Rating	$1.90	$10.00	Outperform
VERV Verve Therapeutics	3/4/2025	Lower Price Target	$5.75	$15.00	Outperform
FDMT 4D Molecular Therapeutics	3/3/2025	Lower Price Target	$4.47	$35.00	Outperform
ALNY Alnylam Pharmaceuticals	2/26/2025	Reiterated Rating	$249.62	$310.00	Outperform
BEAM Beam Therapeutics	2/26/2025	Boost Price Target	$28.85	$26.00	Sector Perform
BMRN BioMarin Pharmaceutical	2/20/2025	Reiterated Rating	$68.99	$70.00	Sector Perform
IONS Ionis Pharmaceuticals	2/20/2025	Reiterated Rating	$32.26	$70.00	Outperform
MRNA Moderna	2/18/2025	Reiterated Rating	$35.72	$40.00	Sector Perform
CRSP CRISPR Therapeutics	2/12/2025	Lower Price Target	$42.75	$48.00	Sector Perform
ARWR Arrowhead Pharmaceuticals	2/11/2025	Reiterated Rating	$18.56	$42.00	Outperform
ALNY Alnylam Pharmaceuticals	2/11/2025	Reiterated Rating	$269.35	$300.00	Outperform
RGNX REGENXBIO	1/21/2025	Reiterated Rating	$7.39	$30.00	Outperform
LXEO Lexeo Therapeutics	1/21/2025	Reiterated Rating	$4.93	$24.00	Outperform
ALNY Alnylam Pharmaceuticals	1/21/2025	Reiterated Rating	$257.98	$300.00	Outperform
QURE uniQure	1/21/2025	Reiterated Rating	$14.50	$24.00	Outperform
SLB Schlumberger	1/21/2025	Reiterated Rating	$44.09	$57.00	Outperform
IONS Ionis Pharmaceuticals	1/15/2025	Reiterated Rating	$33.69	$70.00	Outperform

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.